Thermo Fisher to Acquire Brammer Bio, an Industrial Info Market Brief
Off the heels of purchasing Patheon in 2017, Thermo Fisher is acquiring Brammer Bio, a viral vector contract development and manufacturing organization (CDMO) for gene therapy innovators, for $1.7 billion.
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
